期刊论文The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease复制

DOI:复制

文献链接: https://pubmed.ncbi.nlm.nih.gov/9339268复制

其他信息:

PMID: 9339268
作者: N C Bodick; W W Offen; H E Shannon; J Satterwhite; R Lucas; ...
摘要: The therapeutic effects of selective cholinergic replacement using oral xanomeline, an m1/m4 receptor agonist, were assessed in a multicenter study of 343 patients with Alzheimer disease (AD). Patients were randomized to parallel treatment arms (placebo, 25, 50, and 75 mg t.i.d. xanomeline) and followed through 6 months of double-blind therapy and 1 month of single-blind placebo washout. Completer analysis, using the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog), reve...